Valenva SE, a pure-play vaccine company, recently released an update about the anti-cholera DUKORAL vaccine that it acquired from Crucell Holland BV.
The transition of the acquisition is nearly complete, with Health Canada making requests for alterations to be made with the DUKORAL monograph. Both Valneva and Crucell Holland have settled on modifications that can be made to the product, such as changing the price of the vaccine.
Valneva leaders have confirmed they intend to invest in the vaccine with promotions and geographical expansions. The company aims to focus its resources on important countries as it spreads the vaccine around the world.
“Although the modification of the DUKORAL label may impact the sales potential of the vaccine in Canada, the strategic merits that supported the acquisition of DUKORAL remain unchanged,”
Valneva’s CEO and President Thomas Lingelbach and Deputy Chief Executive Officer Franck Grimaud said in a statement. “This business is expected to be financially sustainable and to represent a complementary fit in support of Valneva’s strategy to build a leading, financially self-sustainable pure-play vaccine company, balancing growth from commercial product contributions and investments in promising R&D vaccine programs. Our previous outlook for reaching operational break-even remains unchanged.”
